Genmab A/S (GB:0MGB)
LSE:0MGB
Want to see GB:0MGB full AI Analyst Report?
0MGB Stock Chart & Stats
kr1804.16
kr20.29(1.27%)
At close: 4:00 PM EST
kr1804.16
kr20.29(1.27%)
Day’s Range― - ―
52-Week Rangekr1,206.00 - kr2,256.00
Previous CloseN/A
Volume5.49K
Average Volume (3M)22.10K
Market Cap
kr101.93B
Enterprise Valuekr63.39B
Total Cash (Recent Filing)kr3.23B
Total Debt (Recent Filing)kr143.00M
Price to Earnings (P/E)126.1
Beta0.88
Next Earnings
May 07, 2026EPS Estimate
9.95Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.17
Shares Outstanding62,350,720
10 Day Avg. Volume15,262
30 Day Avg. Volume22,097
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr2,321.43Price Target Upside28.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical ReadoutsPivotal readouts for Epkinly, Rina‑S, and Peto could materially expand addressable markets and unlock significant valuation upside if they confirm efficacy in their target indications.
Pipeline And Portfolio GrowthRecent acquisitions and a broad late‑stage pipeline create multiple potential revenue drivers that reduce dependence on legacy royalties and support long‑term growth.
Regulatory DesignUse of progression‑free survival as the primary endpoint in key combination trials may streamline regulatory pathways and reduce reliance on overall survival for approvals.
Bears Say
Acquisition ImpactThe Merus acquisition increases financial leverage and is viewed as dilutive to earnings projections, which could pressure the stock as investors reassess balance‑sheet risk.
Clinical Setback And CompetitionMissing the overall survival primary endpoint in the second‑line monotherapy trial represents a notable clinical setback and, together with emerging competitors, could weaken commercial prospects for that indication.
Patent RiskPatent expirations are perceived as underpriced by the market, creating downside risk to future revenue as generic competition enters key product markets.
0MGB FAQ
What was Genmab A/S’s price range in the past 12 months?
Genmab A/S lowest share price was kr1206.00 and its highest was kr2256.00 in the past 12 months.
What is Genmab A/S’s market cap?
Genmab A/S’s market cap is kr101.93B.
When is Genmab A/S’s upcoming earnings report date?
Genmab A/S’s upcoming earnings report date is May 07, 2026 which is in 8 days.
How were Genmab A/S’s earnings last quarter?
Genmab A/S released its earnings results on Feb 17, 2026. The company reported kr3.171 earnings per share for the quarter, missing the consensus estimate of kr17.908 by -kr14.737.
Is Genmab A/S overvalued?
According to Wall Street analysts Genmab A/S’s price is currently Undervalued.
Does Genmab A/S pay dividends?
Genmab A/S does not currently pay dividends.
What is Genmab A/S’s EPS estimate?
Genmab A/S’s EPS estimate is 9.95.
How many shares outstanding does Genmab A/S have?
Genmab A/S has 62,350,720 shares outstanding.
What happened to Genmab A/S’s price movement after its last earnings report?
Genmab A/S reported an EPS of kr3.171 in its last earnings report, missing expectations of kr17.908. Following the earnings report the stock price went up 4.409%.
Which hedge fund is a major shareholder of Genmab A/S?
Currently, no hedge funds are holding shares in GB:0MGB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
0MGB Stock 12 Month Forecast
Average Price Target
kr2,321.43
▲(28.67% Upside)
Technical Analysis
Options Prices
Currently, No data available
---